JPMorgan Chase & Co. lowered its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 80.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 75,500 shares of the company's stock after selling 319,533 shares during the period. JPMorgan Chase & Co. owned approximately 0.08% of Aquestive Therapeutics worth $269,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC grew its stake in shares of Aquestive Therapeutics by 285.4% in the third quarter. Barclays PLC now owns 99,312 shares of the company's stock valued at $495,000 after buying an additional 73,542 shares in the last quarter. Geode Capital Management LLC grew its position in Aquestive Therapeutics by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company's stock valued at $8,306,000 after acquiring an additional 90,543 shares in the last quarter. SG Americas Securities LLC increased its stake in Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock worth $117,000 after purchasing an additional 7,347 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Aquestive Therapeutics by 6.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company's stock worth $3,505,000 after purchasing an additional 61,200 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $69,000. Institutional investors and hedge funds own 32.45% of the company's stock.
Aquestive Therapeutics Stock Performance
AQST stock traded down $0.08 during midday trading on Thursday, reaching $2.65. 218,435 shares of the company were exchanged, compared to its average volume of 1,460,362. The stock's 50-day simple moving average is $2.78 and its 200 day simple moving average is $3.51. Aquestive Therapeutics, Inc. has a 1-year low of $2.20 and a 1-year high of $5.80. The company has a market cap of $263.20 million, a price-to-earnings ratio of -5.89 and a beta of 2.02.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analysts' expectations of $13.11 million. On average, research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. Alliance Global Partners restated a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Wednesday, April 2nd. Lake Street Capital decreased their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Finally, Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $10.67.
Read Our Latest Research Report on Aquestive Therapeutics
About Aquestive Therapeutics
(
Free Report)
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Read More
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
